Abstract
Novel EGFR inhibitors are under development and would provide more options for EGFR exon 20 insertion mutant non-small cell lung cancer (NSCLC) patients, whose treatment options have been limited due to low treatment response of EGFR TKIs such as erlotinib, gefitinib, afatinib, and osimertinib. The candidate inhibitors vary across several attributes including method and frequency of administration, efficacy, side effects, mutation test requirements, and out of pocket cost. There is limited evidence available on Japanese patient and physician preferences that consider the attribute profiles of exon 20 insertion mutation treatments that are currently under development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
